These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23514176)

  • 1. mTORC1 regulates CD8+ T-cell glucose metabolism and function independently of PI3K and PKB.
    Finlay DK
    Biochem Soc Trans; 2013 Apr; 41(2):681-6. PubMed ID: 23514176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells.
    Finlay DK; Rosenzweig E; Sinclair LV; Feijoo-Carnero C; Hukelmann JL; Rolf J; Panteleyev AA; Okkenhaug K; Cantrell DA
    J Exp Med; 2012 Dec; 209(13):2441-53. PubMed ID: 23183047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERK1/2-dependent activation of mTOR/mTORC1/p70S6K regulates thrombin-induced RPE cell proliferation.
    Parrales A; López E; Lee-Rivera I; López-Colomé AM
    Cell Signal; 2013 Apr; 25(4):829-38. PubMed ID: 23291002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTORC1 alters the expression of glycolytic genes by regulating KPNA2 abundances.
    Chen X; Zhu Y; Wang Z; Zhu H; Pan Q; Su S; Dong Y; Li L; Zhang H; Wu L; Lou X; Liu S
    J Proteomics; 2016 Mar; 136():13-24. PubMed ID: 26844761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia.
    Siska PJ; van der Windt GJ; Kishton RJ; Cohen S; Eisner W; MacIver NJ; Kater AP; Weinberg JB; Rathmell JC
    J Immunol; 2016 Sep; 197(6):2532-40. PubMed ID: 27511728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation.
    Pollizzi KN; Patel CH; Sun IH; Oh MH; Waickman AT; Wen J; Delgoffe GM; Powell JD
    J Clin Invest; 2015 May; 125(5):2090-108. PubMed ID: 25893604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1→HIF-1α pathway.
    Argyriou P; Papageorgiou SG; Panteleon V; Psyrri A; Bakou V; Pappa V; Spathis A; Economopoulou P; Papageorgiou E; Economopoulos T; Rontogianni D
    Ann Hematol; 2011 Mar; 90(3):315-22. PubMed ID: 20838824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulators of Glucose Metabolism in CD4
    Palmer CS; Hussain T; Duette G; Weller TJ; Ostrowski M; Sada-Ovalle I; Crowe SM
    Int Rev Immunol; 2016 Nov; 35(6):477-488. PubMed ID: 26606199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy.
    Martelli AM; Tabellini G; Ricci F; Evangelisti C; Chiarini F; Bortul R; McCubrey JA; Manzoli FA
    Adv Biol Regul; 2012 Jan; 52(1):214-27. PubMed ID: 21983557
    [No Abstract]   [Full Text] [Related]  

  • 10. PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma.
    Mohlin S; Hamidian A; von Stedingk K; Bridges E; Wigerup C; Bexell D; Påhlman S
    Cancer Res; 2015 Nov; 75(21):4617-28. PubMed ID: 26432405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5-Dependent Activation of mTORC1 Regulates Translation of Inducible NO Synthase and COX-2 during Encephalomyocarditis Virus Infection.
    Shaheen ZR; Naatz A; Corbett JA
    J Immunol; 2015 Nov; 195(9):4406-14. PubMed ID: 26408666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foxp3 and Toll-like receptor signaling balance T
    Gerriets VA; Kishton RJ; Johnson MO; Cohen S; Siska PJ; Nichols AG; Warmoes MO; de Cubas AA; MacIver NJ; Locasale JW; Turka LA; Wells AD; Rathmell JC
    Nat Immunol; 2016 Dec; 17(12):1459-1466. PubMed ID: 27695003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation.
    Nagai S; Kurebayashi Y; Koyasu S
    Ann N Y Acad Sci; 2013 Mar; 1280():30-4. PubMed ID: 23551100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase/PKB, mediated signaling pathways in T lymphocytes.
    Genot E; Reif K; Beach S; Kramer I; Cantrell D
    Oncogene; 1998 Oct; 17(13):1731-8. PubMed ID: 9796702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of hypoxia-inducible factor 1 in human T-cell leukaemia virus type 1-infected cell lines and primary adult T-cell leukaemia cells.
    Tomita M; Semenza GL; Michiels C; Matsuda T; Uchihara JN; Okudaira T; Tanaka Y; Taira N; Ohshiro K; Mori N
    Biochem J; 2007 Sep; 406(2):317-23. PubMed ID: 17576198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent Antigen and Prolonged AKT-mTORC1 Activation Underlie Memory CD8 T Cell Impairment in the Absence of CD4 T Cells.
    Li Y; Shen C; Zhu B; Shi F; Eisen HN; Chen J
    J Immunol; 2015 Aug; 195(4):1591-8. PubMed ID: 26163589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-translational regulation of mTOR complex 1 in hypoxia and reoxygenation.
    Tan CY; Hagen T
    Cell Signal; 2013 May; 25(5):1235-44. PubMed ID: 23416465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hexosamine biosynthesis pathway and O-GlcNAcylation maintain insulin-stimulated PI3K-PKB phosphorylation and tumour cell growth after short-term glucose deprivation.
    Jones DR; Keune WJ; Anderson KE; Stephens LR; Hawkins PT; Divecha N
    FEBS J; 2014 Aug; 281(16):3591-608. PubMed ID: 24938479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism.
    Chen GQ; Tang CF; Shi XK; Lin CY; Fatima S; Pan XH; Yang DJ; Zhang G; Lu AP; Lin SH; Bian ZX
    Oncotarget; 2015 Sep; 6(27):24148-62. PubMed ID: 26160839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.